MS Clinical Trials
You Can Become Part of the Solution
Become part of the MS treatment solution by participating in a clinical trial at The Boster Center.
For more information about clinical trials, listen to an interview from Real Talk MS – Everything You Need to Know About Clinical Trials with Dr. Aaron Boster.
Unlock the Potential of MS Treatments with Clinical Research Trials
Clinical Research Trials in which You Can Participate
We understand it can be frustrating trying to manage your MS symptoms while also fine-tuning your treatment protocols. Dr. Aaron Boster has extensive experience conducting clinical trials to develop a range of multiple sclerosis treatments.
The Boster Center is currently leading in international enrollment in several of its MS clinical trials. We are accepting patient enrollment in several MS clinical trials and we are also following patients in several ongoing trials that are close to enrollment, as shown below.
Clinical Trials Open for Enrollment at The Boster Center
At The Boster Center, we strive to find disease modifying therapies so patients can live a better life. We are recruiting people to participate in the following MS-related research studies:
FENhance 1
(Roche/Genentech)
A Phase 3 multicenter, randomized, double-blind, double-dummy, parallel-group study to evaluate the safety and efficacy of Fenebrutinib compared with Teriflunomide (Aubagio®) in adult patients with relapsing multiple sclerosis.
For patients with RRMS or active SPMS between the ages of 18-55. Compares investigational product Fenebrutinib (BTK Inhibitor) versus Aubagio®.
REMODEL II
(Novartis Pharmaceuticals)
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of Remibutinib versus Teriflunomide (Aubagio®) in participants with relapsing multiple sclerosis, followed by extended treatment with open-label Remibrutinib.
For patients with RRMS or active SPMS between the ages of 18-55. Compares investigational product Remibrutinib (BTK Inhibitor) versus Aubagio®.
CALLIPER
(Immune Therapeutics)
A multicenter, randomized, double-blind, placebo-controlled study to evaluate efficacy, safety, and tolerability of IMU-838 (Vidofludimus Calcium) in patients with progressive multiple sclerosis.
For patients with PPMS and non-relapsing SPMS between the ages of 18-65. Compares investigational product Vidofludimus Calcium (DHODH Inhibitor) versus a placebo.
OPERETTA 2
(PPD/Roche)
A Phase 3 multicenter, randomized, double-blind, double-dummy study to evaluate the safety and efficacy of Ocrelizumab (Ocrevus) in comparison with Fingolimod (Gilenya) in children and adolescents with relapsing-remitting multiple sclerosis.
For patients with pediatric RRMS between the ages of 10-18. Compares Ocrevus (FDA Approved for adult RMS and PPMS patients) to Gilenya.
Aging Study MS700568_0185
A multicenter, observational study to characterize the clinical course in a real-world, U.S. cohort of patients with relapsing multiple sclerosis of advanced age (≥ 50 years) treated with Cladribine tablets (Mavenclad).
For patients with RRMS or SPMS over the age of 50 that have initiated Mavenclad before 31 January 2022.
CogMS
A real-world study into cognitive impairment in people with multiple sclerosis to investigate the correlation between objective and subjective cognition in multiple sclerosis.
Fusion-RMS
(Biogen)
A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2
Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091
Combination Therapy With Diroximel Fumarate in participants With relapsing forms of multiple
sclerosis.
O’HAND
(Roche)
A Phase IIIb Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ocrelizumab in adults with primary progressive multiple sclerosis.
CorEvitas
CorEvitas Multiple Sclerosis (MS) Registry to collect important doctor and patient-reported outcomes to help improve the understanding of MS.
CorEvitas SPHERES
CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD) to study the natural history of NMOSD, real-world effectiveness, and safety of medications used to treat NMOSD, and drug utilization treatment patterns.
Master 2
Observational evaluation of effectiveness and patient-reported outcomes (PROs) in suboptimally controlled patients previously Taking oral or infusion disease-modifying drugs (DMDs) for relapsing forms of multiple sclerosis (RMS).
Active Studies at The Boster Center, but No Longer Enrolling
Because we want to stay on the cutting edge of MS clinical research, we have several studies that are closed to enrollment, but still ongoing:
GEMINI 1 – EFC16033
(Sanofi)
A Phase 3, randomized, double-blind efficacy and safety study comparing SAR442168 (Tolebruntinib) to teriflunomide (Aubagio®) in participants with relapsing forms of MS. (GEMINI 1)
For patients with RMS between the ages of 18-55. Compares investigational product Tolebrutinib (BTK Inhibitor) versus Aubagio®.
PERSEUS – EFC16035
(Sanofi)
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 (Toleburtinib) to placebo in patients with primary progressive multiple sclerosis.
For patients with PPMS between the ages of 18-55. Compares investigational product Tolebutinib (BTK Inhibitor) versus a placebo.
HERCULES – EFC16645
(Sanofi)
A Phase 3, randomized, double-blind, efficacy and safety study comparing SAR442168 to placebo in participants with non-relapsing secondary progressive multiple sclerosis.
For patients with SPMS between the ages of 18-55. Compares investigational product Tolebutinib (BTK inhibitor) versus a placebo.
BIIB091 Monotherapy & BIIB091 Combination Therapy
A 2-part, multicenter, randomized, blinded, active-controlled Phase 2 study to sequentially evaluate the safety and efficacy of BIIB091 monotherapy and BIIB091 combination therapy With Diroximel Fumarate in participants with relapsing forms of multiple sclerosis.
Remibrutinib vs. Teriflunomide
A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of Remibrutinib versus Teriflunomide in participants with relapsing multiple sclerosis, followed by extended treatment with open-label Remibrutinib.
What to Expect During Your Clinical Trial
During a clinical trial at The Boster Center, you will be under the expert supervision of Dr. Boster and his staff. Dr. Boster is a leading specialist in MS and will be with you every step of the way through your treatment plan.
Select Your Study
Look at the MS clinical trials currently accepting enrollment to see if there are any for which you may qualify.
Inquire About Participation
Contact us to let us know that you would like to be considered for the study (or studies) you selected.
Be Evaluated
Dr. Boster and his team will interview you, review your medical history, and evaluate your candidacy for the research study.
Make the Difference
Begin your clinical trial knowing you’re getting the best possible treatment while making an important contribution to MS treatment.
Watch Our Videos To Learn More
Be a Groundbreaker in the Fight Against Multiple Sclerosis
As a groundbreaker in the fight against multiple sclerosis, you can join us in discovering new solutions and treatments for MS.
At The Boster Center, we are passionate about research and development, and we are dedicated to finding treatments that are effective and accessible to everyone.
We are confident, together, we can make a difference in the fight against MS.
Frequently Asked Questions
What are the symptoms of multiple sclerosis?
Multiple sclerosis symptoms can vary from person to person, but common ones include muscle weakness or stiffness, balance problems, vision problems, trouble walking, numbness or tingling in the body, fatigue, and memory loss. Some people also experience depression or mood changes.
Will there soon be a cure for multiple sclerosis?
While there is currently no cure for multiple sclerosis, research (like that being done at The Boster Center) is bringing us closer each day to more effective and longer-lasting treatments.
What is the latest research on multiple sclerosis?
Multiple sclerosis is a disease that affects the functioning of the brain and body. Recently, researchers have been looking into ways to treat the disease and delay disability progression. This includes trying different drugs, physical therapy, and lifestyle changes like diet and exercise. Researchers are also exploring the use of stem cell therapy to replace damaged cells in the brain and body, which could help improve symptoms of the disease.
What is a phase 1 clinical trial?
A phase 1 clinical trial is a research study that tests a new drug or treatment in people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects. The Boster Center is currently conducting clinical trials for multiple sclerosis and other neurologic diseases.
What is a phase 2 clinical trial?
A phase 2 trial is a study of people to see how well a new drug works and to find out what side effects and safety risks it may have. This study is usually larger than a phase 1 trial and may involve hundreds of people.
What is a phase 3 clinical trial?
In a phase 3 clinical trial, the new drug or treatment is studied to determine if it works better than current treatments and to find out what side effects and safety risks it may have. Phase 3 trials are the last stage of testing in a drug's development process. These trials are usually the most important part of the drug development process.
What is a phase 3B clinical trial?
Like the phase 3 trial, the phase 3B clinical trial is a study in people to see if a new drug or treatment works better than current treatments and to find out what side effects and safety risks it may have. But at this phase of the study, the subject pool is generally much larger and may involve hundreds or even thousands of people.
Is there hope for MS?
Yes, there is hope for people with multiple sclerosis. With early diagnosis and the right treatments, people with MS can manage the symptoms of their disease and live active and fulfilling lives. There are new treatments being developed each day and clinical trials just like those being performed at The Boster Center, giving hope for even more advancements in the future.
Can stem cell treatment help MS?
Stem cell treatment is a type of scientific therapy that uses stem cells from the patient or from a donor to help repair damaged or destroyed cells in the body. For people with multiple sclerosis (MS), stem cell treatment can help replace damaged cells in the brain and can help reduce the symptoms of the disease.
What treatments are available for multiple sclerosis?
Treatment studies are currently underway at The Boster Center. To learn more, contact The Boster Center today at (614) 304-3444 or contactus@bosterms.
What causes multiple sclerosis?
How is multiple sclerosis diagnosed?
Multiple sclerosis is usually diagnosed by a combination of physical exams and medical tests. Doctors may conduct blood tests, eye exams, and magnetic resonance imaging (MRI) scans to look for specific changes in the brain and spinal cord. They might also look for changes in the nerve impulses sent from the brain to other parts of the body.
What are the long-term effects of multiple sclerosis?
Over time, the effects of MS can cause difficulties with walking, speaking, thinking, and more. It can also cause fatigue, pain, and emotional problems. In the long term, there's no cure, but treatments can help people with MS manage their symptoms and live a satisfying life.
What lifestyle changes can be made to help manage multiple sclerosis?
When you have multiple sclerosis, it's important to make some lifestyle changes to help you stay healthy. You should try to exercise regularly, eat a healthy diet, get enough sleep, and maintain a regular schedule. You should also avoid smoking, alcohol, caffeine, and other substances to help manage your symptoms. Lastly, make sure to talk to your doctor regularly and follow their advice.
